ANNOVIS BIO
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
ANNOVIS BIO
Industry:
Biotechnology Developer Platform Therapeutics
Founded:
2008-01-01
Address:
Berwyn, Pennsylvania, United States
Country:
United States
Website Url:
http://www.annovisbio.com
Total Employee:
1+
Status:
Active
Contact:
(610)727-3913
Email Addresses:
[email protected]
Total Funding:
58.98 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro GStatic Google Static Content Sectigo SSL Sectigo Domain SSL PostalAddress Schema
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Employees Featured
Founder
Stock Details
Investors List
Robin Hood Ventures
Robin Hood Ventures investment in Post-IPO Equity - Annovis Bio
Robin Hood Ventures
Robin Hood Ventures investment in Series A - Annovis Bio
Robin Hood Ventures
Robin Hood Ventures investment in Series A - Annovis Bio
Delaware Crossing Investor Group
Delaware Crossing Investor Group investment in Series A - Annovis Bio
Michael Hoffman
Michael Hoffman investment in Series A - Annovis Bio
Keiretsu Forum
Keiretsu Forum investment in Series A - Annovis Bio
BioAdvance
BioAdvance investment in Seed Round - Annovis Bio
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania investment in Seed Round - Annovis Bio
BioAdvance
BioAdvance investment in Debt Financing - Annovis Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-29 | Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer |
Official Site Inspections
http://www.annovisbio.com Semrush global rank: 4.5 M Semrush visits lastest month: 2.39 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Annovis Bio"
About Us - ANNOVIS BIO
Ms. Damiano has spent over 35 years in the biotechnology sector, focusing on the definition and execution of regulatory strategies and GxP compliance, encompassing early phase development through commercialization.See details»
Corporate Governance - annovisbio.com
Join the Annovis Bio Newsletter to receive the latest updates on our groundbreaking research and developments in neurodegenerative diseases like Alzheimer's and Parkinson'sSee details»
Annovis Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (610)727-3913 Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), …See details»
Annovis Bio - Overview, News & Similar companies - ZoomInfo
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel …See details»
Annovis Bio Provides Data Announcement Update for the Phase …
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative …See details»
Annovis Bio, Inc. | LinkedIn
Annovis Bio, Inc. Biotechnology Research Malvern, Pennsylvania 3,057 followers It’s time for a new direction in treating Alzheimer’s, Parkinson’s and related neurodegenerative diseases.See details»
QR Pharma Adopts new Corporate Name: Annovis Bio
Jun 24, 2019 While carrying forward the research QR Pharma pioneered in this field, the new name Annovis connotes this deeper understanding and the organization’s new direction …See details»
Annovis to Host Year-End Investor Webcast on December 11, 2024
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for …See details»
Annovis Bio Receives FDA Approval to Transition to New Crystal …
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...See details»
Annovis Bio Provides Corporate Updates and Announces First …
First Quarter 2024 Financial Results. The Company’s cash and cash equivalents totaled $3.1 million as of March 31, 2024, compared to $5.8 million as of December 31, 2023.See details»
Annovis Bio Provides Data Announcement Update for the Phase
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...See details»
Change reflects enhanced focus on neurodegenerative diseases
Neurodegenerative diseases, today announced that the name of the organization is changing from “QR Pharma, Inc.” to “Annovis Bio, Inc.” “Our new name – Annovis – communicates the …See details»
Annovis Bio Receives FDA Approval to Transition to New
Jul 16, 2024 www.annovisbio.com. Investor Contact. Scott McGowan InvestorBrandNetwork (IBN) Phone: 310.299.1717 [email protected] Investor Website. Tags Annovis Bio Inc. ...See details»
Annovis Bio Provides Corporate Updates and Announces First …
For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and X (formerly known as Twitter). Forward-Looking Statements …See details»
Annovis Bio, Inc. (ANVS) - Yahoo Finance Canada
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has …See details»
Annovis Bio - YouTube
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other ch...See details»
Our Science - ANNOVIS BIO
Buntanetap (previously known as Posiphen) is a translational inhibitor of neurotoxic aggregating proteins. Different from monoclonal antibody therapies, buntanetap is an orally available small …See details»
Annovis Bio, Inc. (ANVS) Stock Price, Quote & News - Stock Analysis
About ANVS. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has …See details»
Investor Relations - EQS Group
ANVS is an innovative company dedicated to advancing the treatment of neurodegenerative diseases by developing groundbreaking therapies that address Alzheimer's, Parkinson's, and …See details»